Prof. PeptideProf. Peptide

Epitalon

LongevityResearch-Grade

Last reviewed: September 20, 2026

Quick Facts

What it is
A synthetic tetrapeptide (AEDG) studied in longevity research for telomerase activation, telomere lengthening, and restoration of the pineal/melatonin circadian rhythm in aging.
How it's taken
Subcutaneous injection, once daily during a 10–20 day cycle (bedtime preferred)
Half-life
~30 minutes (plasma) — effects persist via gene expression
Typical research dose
0.5–1 mg daily (5–10 mg per cycle), 2–4 cycles per year
Research status
Not FDA-approved — research use only.
On this page
  1. 1.Where to source Epitalon
  2. 2.What is Epitalon?
  3. 3.How does Epitalon work?
  4. 4.What is Epitalon used for?
  5. 5.How long does Epitalon take to work?
  6. 6.How is Epitalon dosed?
  7. 7.How is Epitalon administered?
  8. 8.What does Epitalon stack well with?
  9. 9.What are the side effects of Epitalon?
  10. 10.Does Epitalon interact with other drugs?
  11. 11.How should Epitalon be stored?
  12. 12.What are the limitations of Epitalon research?
  13. 13.Epitalon FAQ
  14. 14.References
  15. 15.Published Studies
  16. 16.In the News

Where to source Epitalon

Epitalon is not FDA-approved and is sold by specialty research peptide vendors. Quality varies dramatically across vendors — verify Certificate of Analysis before purchase. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 47 vendors

Also stocking Epitalon

Peptides.gg, Royal Peptides, Vital Core Research, Ameano Peptides — each carries a current price row for this compound.

Compare all 47 vendors stocking Epitalon

See all 88 verified vendors

What is Epitalon?

Epitalon (also spelled Epithalon, and written as the AEDG tetrapeptide or Ala-Glu-Asp-Gly) is a synthetic tetrapeptide (alanine-glutamate-aspartate-glycine) developed in the 1980s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It was synthesized as a short-peptide analog of epithalamin, a natural pineal gland extract that Khavinson and colleagues studied for decades in Soviet-era gerontology research. Epitalon's most-cited mechanism is telomerase activation, which extends the protective telomere caps on chromosomes — a process linked to cellular aging. The multi-decade Russian cohort research reporting reduced mortality in elderly subjects (Khavinson & Morozov 2003, PMID 14523363, 266 subjects over 6-8 years) treated Thymalin and Epithalamin — the natural gland-extract preparations, not synthetic Epitalon itself — and that human mortality data does not carry over to Epitalon. The synthetic AEDG peptide's own evidence includes a rat reproductive-aging model (Arutjunyan et al. 2012, PMID 23237594), in vitro human-cell telomerase work, and one short human ocular report (Khavinson et al. 2002, PMID 12195242, retinitis pigmentosa via parabulbar injection; a 2025 review gives 162 patients over 10 days with no reported side effects in the treated group) — not systemic or long-term human data. A 2025 cell-culture study from an unaffiliated UK group (Al-Dulaimi et al., Biogerontology; two breast-cancer lines plus normal epithelial cells and fibroblasts) reported dose-dependent telomere lengthening in the normal cells via hTERT upregulation; a published correction replaced three of its figures. Often paired with NAD+ or GHK-Cu for layered longevity protocols. New to peptide research? Start with the basics

Reported benefits:

  • Telomerase activation and telomere lengthening (cell culture and animal evidence; a 2025 cell-line study from an unaffiliated group reported a similar result)
  • Restoration of melatonin rhythm in aging
  • Improved circadian function and sleep architecture
  • Correction of disturbed circadian rhythms in a rat reproductive-aging model (animal evidence)
  • Anti-aging gene expression modulation
  • Pineal gland support and endogenous antioxidant enzyme upregulation

Common research dose: Subcutaneous injection: 5–10 mg per cycle, divided over 10–20 days (typically 0.5–1 mg/day). Reported cycle: a 10–20 day intensive course, with 2–6 months between cycles. Some users do 2–4 cycles per year. Bedtime injection is preferred to align with the pineal/melatonin pathway.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does Epitalon work?

Epitalon's most-cited mechanism is telomerase activation — it binds to ATTTC sequences in the promoter region of the telomerase gene and upregulates expression of hTERT (the catalytic subunit of telomerase). Activating telomerase extends the protective telomere caps on chromosomes, a process linked to cellular aging. Epitalon also restores pineal melatonin production in aging populations, modulates circadian gene expression, and enhances endogenous antioxidant enzyme activity. The five hallmarks-of-aging it touches are the basis for its longevity-research framing.

  1. Telomerase Activation [1][2]. Cell culture studies show Epitalon activates telomerase, the enzyme that maintains chromosomal telomeres. Telomere shortening is a hallmark of cellular aging; telomerase activation potentially extends cellular replicative lifespan. Originally a Khavinson-lab finding (2003); a 2025 cell-culture study by an unaffiliated group (Al-Dulaimi et al.; breast-cancer lines plus normal cells, later corrected) reported hTERT upregulation in the normal cells.
  2. Pineal Gland Modulation [3]. Originally derived from epithalamin (pineal extract). Restores age-related decline in melatonin production. Melatonin rhythm restoration is a key claim in Russian gerontology research and a consistent finding in aged monkeys and humans.
  3. Gene Expression. Modulates expression of genes related to circadian rhythm, antioxidant defense, and apoptosis regulation.
  4. Antioxidant Activity. Increases activity of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) in animal models.
  5. Circadian Rhythm Restoration. Pineal-mediated melatonin rhythm restoration improves sleep architecture and overall circadian function in aging populations.

What is Epitalon used for?

Epitalon's research evidence base sits in telomere biology (cell culture and animal), sleep and circadian restoration in animal models, animal lifespan studies (in mice, maximum but not mean lifespan increased), and limited cancer-prevention research in mice. The multi-decade Russian human mortality-reduction cohort research is real but studied Thymalin and Epithalamin, natural gland extracts, not synthetic Epitalon itself. A 2025 UK replication (Al-Dulaimi et al.) significantly strengthens the telomerase-activation evidence for Epitalon specifically. One short-term human trial of synthetic Epitalon itself has been identified — an ocular (parabulbar-injection) study in Retinitis pigmentosa patients — but it does not establish a systemic or longevity-relevant human dose.

  1. Telomerase & Telomere Lengthening [1][2]. Khavinson's lab reported telomerase activation in human somatic cells in culture. Al-Dulaimi et al. (2025), an unaffiliated group, tested breast-cancer cell lines and normal cells and reported dose-dependent telomere extension in the normal cells via hTERT upregulation; a published correction replaced three of its figures. Both are cell-culture reports.
  2. Russian Long-Term Cohort Studies [5]. Khavinson & Morozov 2003 (PMID 14523363) followed 266 elderly subjects for 6-8 years and reported reduced mortality with Thymalin and Epithalamin — natural gland-extract preparations, not the synthetic Epitalon peptide this page profiles. This is real, multi-decade human data, but it does not establish an effect for Epitalon itself.
  3. Human Trial — Retinitis Pigmentosa (ocular route) [9]. Khavinson et al. 2002 (PMID 12195242) reports Epitalon treatment for retinitis pigmentosa via parabulbar ocular injection, finding a positive clinical effect in 90% of cases; the primary paper's own abstract does not give the patient count, control-group design, or specific effect sizes. A 2025 review [3] summarizes those specifics: a trial at the St. Petersburg Institute of Bioregulation and Gerontology in 162 patients (age 18-72), given 5.0 mcg of Epitalon per eye for 10 consecutive days against a conventionally-treated control group, with improved visual acuity and visual field versus control and no reported side effects — those specific figures are sourced to the review's summary, not independently confirmed in the primary paper's own text. This is Human Observational evidence for a topical/ocular route and a specific eye condition; it does not establish a systemic or subcutaneous human dose.
  4. Sleep & Circadian [3]. Restoration of disturbed circadian dopamine/norepinephrine rhythms was demonstrated directly for synthetic Epitalon in a rat reproductive-aging model (Arutjunyan et al. 2012, PMID 23237594). Improved sleep quality in humans is community-reported, not established in a controlled study.
  5. Animal Lifespan [3]. Drosophila lifespan extended by up to 16%; chick, mouse, and rat lifespan extension reported in Russian research. In one mouse study (Anisimov 2003, PMID 14501183), mean lifespan was unchanged and maximum lifespan was 12.3% longer than controls. Effect sizes vary; methodology not always Western-standard.
  6. Cancer Research [3]. Reduced spontaneous tumor incidence and metastases reported in mouse models. The 2025 Al-Dulaimi study found cancer cells extend telomeres via ALT pathway rather than hTERT — relevant context for the theoretical telomerase-in-cancer concern.

How long does Epitalon take to work?

Epitalon effects develop on multiple timescales. Acute effects (sleep quality, circadian rhythm) are measurable in 1–2 weeks of cycling. Telomerase activation effects accumulate over months. Multi-cycle protocols typically run 2–4 cycles over a year. Long-term effects (the framing used in Russian cohort research) are measured over years rather than weeks.

Acute effects (sleep quality, circadian rhythm) are typically measurable in the first 1–2 weeks of cycling. Most users report better sleep architecture and more consistent sleep onset within the first week. Telomerase activation effects accumulate gradually over months; the cell-culture evidence shows multiple cell-doubling extensions, but in-vivo measurement of telomere length in blood cells over a single cycle is at the edge of detection. Multi-cycle protocols (2–4 cycles per year) are the standard framing in Russian gerontology research, with long-term effects measured over years.

How is Epitalon dosed?

No trial has established a subcutaneous, longevity-focused dose for Epitalon. The figures below are split into what the cited literature administered and, separately, community-reported practice.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

Human trial, ocular route (Retinitis pigmentosa) [9]. Khavinson et al. 2002 (PMID 12195242) reports Epitalon treatment for retinitis pigmentosa by parabulbar injection (injected near, not into, the eyeball), finding a positive clinical effect in 90% of cases. A 2025 review [3] summarizes the trial design as 5.0 mcg of Epitalon per eye once daily for 10 consecutive days to 162 patients aged 18–72 at the St. Petersburg Institute of Bioregulation and Gerontology, against a conventionally-treated control group — those specific figures are sourced to the review, not independently confirmed in the primary paper's own abstract. This is Human Observational evidence for an ocular condition and route — it does not establish a subcutaneous or systemic dose.

Animal and in vitro dosing [3]. In rats, 100 mcg of Epitalon given orally once daily for 1 month increased intestinal glucose transport. In cultured pigmented and retinal epithelial cells, a 10 ng/mL concentration over 28 days produced the strongest proliferative effect among the concentrations tested — notably not the highest concentration used. Neither figure translates to a human systemic dose; they are animal-model and in-vitro figures, reported here as what those specific experiments used.

Adverse events at the human trial dose [9]. Khavinson et al. 2002 does not report a specific adverse-event count in its own abstract; the 2025 review states none of the 162 Epitalon-treated patients in its summary of the ocular trial reported side effects over the 10-day course. No adverse-event data exists for subcutaneous or longer-duration use in humans.

Community-reported practice (unverified)

Reported research-community practice — attributed to Russian gerontology protocols and where it circulates online, not to the trial or animal data above, and not independently verified by Prof. Peptide — is 5–10 mg total dose per cycle, divided as 0.5–1 mg subcutaneously daily for 10–20 days, repeated 2–4 times per year with 2–6 months between cycles, with bedtime injection preferred to align with pineal/melatonin pathway timing. This diverges sharply from every cited figure above: the route differs (subcutaneous versus the trial’s ocular parabulbar injection or the rat study’s oral dosing), the population differs (longevity users versus Retinitis pigmentosa patients or rats), and the per-dose magnitude is roughly 100–200× the trial’s 5 mcg ocular dose and roughly 5–10× the rat study’s 100 mcg oral dose — though doses across species and routes are not directly comparable. Some users report sublingual protocols; evidence for oral or sublingual bioavailability in humans has not been identified.

Reconstitution. 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL. See How is Epitalon administered? for the full reconstitution table.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is Epitalon administered?

Epitalon is given as a subcutaneous injection — under the skin, not into muscle — once daily during the cycle, using a small insulin syringe. Bedtime is the preferred injection time to align with the natural pineal/melatonin pathway. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection, once daily during the cycle. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Bedtime preferred — aligns with pineal/melatonin pathway timing.
  3. With or without food. Either is fine; no fasting requirement.
  4. Site rotation. Rotating sites each day, with at least an inch between consecutive sites, is the convention for limiting localized irritation.
  5. Missed dose. Reported practice skips and resumes the next day. The convention is not to double-dose.
  6. Reconstitution handling. Bacteriostatic water is reported added slowly down the inside wall of the vial, with a gentle swirl rather than shaking.
  7. Cycle structure. Single 10–20 day intensive cycle, then 2–6 month break. Lifelong cycling (2–4 cycles per year) is the conventional framing.

Timing context. Epitalon is administered once daily via subcutaneous injection during the cycle. Plasma half-life is short (~30 minutes), but the biological effects are driven by gene-expression changes that persist far longer than the peptide's presence in circulation. The two timing variables that matter most are cycle consistency (daily during the 10–20 day intensive cycle) and time of day (bedtime preferred to align with pineal/melatonin pathway).

AspectReported
FrequencyOnce daily during a 10–20 day cycle, 2–4 cycles per year, per Russian gerontology protocols and community convention — not Western trial-derived
Best time of dayBedtime — aligns with pineal/melatonin pathway timing
FoodNo fasting required; inject with or without food
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to Epitalon.
Half-life~30 minutes (plasma) — biological effects persist via gene-expression changes
Steady-stateNot pharmacologically meaningful — effects accumulate via gene-expression rather than plasma steady-state

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. Epitalon research vials are typically 10 mg. Because Epitalon daily doses are small (0.5–2 mg), 2 mL reconstitution is the common research convention — it gives clean whole-number units across the typical dose range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 10 mg vial.

BAC waterConcentration0.5 mg dose1 mg dose1.5 mg dose2 mg dose
1 mL10 mg/mL5 units10 units15 units20 units
2 mL5 mg/mL10 units20 units30 units40 units
3 mL3.33 mg/mL15 units30 units45 units60 units

Units vs mcg. At a 10 mg vial, each unit drawn delivers 100 mcg (0.1 mg) of Epitalon at 1 mL reconstitution, 50 mcg at 2 mL, and 33 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does Epitalon stack well with?

Epitalon pairs naturally with other longevity peptides because its mechanism (telomerase activation + pineal/circadian restoration) is non-overlapping with most other anti-aging interventions. The cleanest additions are NAD+ (cellular metabolism), GHK-Cu (regenerative gene expression), and standard longevity protocols (resveratrol, NMN, omega-3, vitamin D). Epitalon is not paired with the muscle-building or recovery blend stacks — its lane is longevity-cellular-health, not performance.

  1. NAD+. NAD+ is the most common longevity stack pairing. Cellular metabolism + cellular aging mechanisms are non-overlapping and addressed simultaneously. See the Epitalon vs NAD+ comparison for protocol differences.
  2. GHK-Cu. GHK-Cu for combined cellular regeneration + telomere protection. Reviews by GHK-Cu's discoverer report ~4,000 genes with shifted expression in cell-line database data; Epitalon's studied mechanism is telomerase activation.
  3. Standard longevity protocols. Resveratrol, NMN, omega-3, vitamin D — all compatible. Mechanisms are non-overlapping with Epitalon.
  4. Exogenous melatonin. Supportive for pineal function during cycles — but Epitalon is intended to restore endogenous melatonin production, not replace it, so exogenous melatonin is often tapered as Epitalon takes effect.
  5. Conflicts: high-dose direct telomerase inhibitors. Mostly experimental research compounds — theoretical antagonism of Epitalon's primary mechanism.

What are the side effects of Epitalon?

The decades-long Russian cohort record often cited for Epitalon belongs to Thymalin and Epithalamin, the natural gland-extract preparations, not the synthetic AEDG peptide. Synthetic Epitalon's own human data is narrower: Khavinson et al. 2002 (PMID 12195242) reports Epitalon treatment for retinitis pigmentosa (parabulbar ocular injection); a 2025 review (Araj et al.) summarizes it as 162 patients over 10 days with no side effects in the treated group, a specific figure this page sources to that review, not the primary paper's own text — but even so, that is a short, ocular-route report, not systemic or long-term safety data. Reported effects for the subcutaneous route research users actually take are community-reported and mild — injection site reactions, occasional vivid dreams during cycles (consistent with the pineal/melatonin pathway), mild headache — not derived from a controlled study of that route. The single theoretical concern is telomerase activation in cancer contexts; no study of Epitalon in people with cancer was found.

Common (most users)

  1. Injection site reactions. Mild redness or irritation, typically resolves within hours.
  2. Vivid dreams or mild sleep changes. Consistent with the pineal/melatonin pathway; reported during cycles, typically resolves after cycle ends.

Less common (moderate)

  1. Mild headache. Uncommon, typically mild and self-limited.
  2. Mild fatigue. Inconsistent across users.

Serious (rare)

  1. No systemic or long-term human safety data for Epitalon itself. The 20+ year Russian cohort safety record belongs to Thymalin and Epithalamin (natural extracts), not the synthetic Epitalon peptide. A short ocular-route report exists (Khavinson et al. 2002, PMID 12195242; reported by a 2025 review as 162 patients, 10 days, no side effects in the treated group) but does not establish systemic or long-term safety.
  2. Theoretical cancer concern. Telomerase activation in cancer contexts is theoretically concerning — though the 2025 Al-Dulaimi study found cancer cells extend telomeres via ALT pathway rather than hTERT. No study of Epitalon in people with cancer was found.

Epitalon has decades of documented Russian human use under research conditions. NOT FDA-approved. Whether telomerase activation is safe alongside an active cancer is an oncology question the published data does not answer.

Does Epitalon interact with other drugs?

Epitalon has no documented major drug-drug pharmacokinetic interactions at standard cycling doses. The main considerations are sleep medications (Epitalon may shift natural melatonin rhythm; monitor sleep onset), SSRIs (limited data), and cancer therapies (theoretical concern with telomerase activation — consult oncologist).

  1. Sleep medications. Epitalon may shift natural melatonin rhythm; monitor for changes in sleep onset, particularly during the first cycle.
  2. SSRIs. Limited data; no documented interactions in published research.
  3. Cancer therapies. Telomerase activation in a cancer context is a theoretical concern that the published data does not resolve.
  4. No documented major drug-drug pharmacokinetic interactions at standard cycling doses.

How should Epitalon be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; 2–8°C acceptable for short-term.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade Epitalon remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is not frozen.
  5. Epitalon is stored protected from light, in the original packaging.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of Epitalon research?

Epitalon is not FDA-approved. Its human clinical evidence is limited to one short ocular report — Khavinson et al. 2002 (PMID 12195242), retinitis pigmentosa, parabulbar injection; a 2025 review gives the specifics as 162 patients over 10 days — the multi-decade Russian mortality-reduction cohort research (Khavinson and colleagues) that is often cited for it actually studied Thymalin and Epithalamin, natural gland-extract preparations, not Epitalon. The telomerase activation mechanism is the most scientifically interesting claim. A 2025 cell-line study from an unaffiliated UK group (Al-Dulaimi et al.; breast-cancer and normal cells, later corrected) reported a similar result, but that work, like Epitalon's animal evidence, is preclinical. Epitalon is NOT currently on the WADA prohibited list.

Epitalon is NOT FDA-approved. Its human clinical evidence is limited to one short trial: Khavinson et al. 2002 (Neuro Endocrinol Lett, PMID 12195242) reports Epitalon treatment in patients with degenerative retinal lesions (retinitis pigmentosa), finding a positive clinical effect in 90% of cases. The paper's own abstract does not state the patient count, control-group design, or effect-size figures often quoted for it; a 2025 review (Araj et al., Int J Mol Sci, PMC11943447) summarizes those specifics — 162 patients aged 18-72, 5.0 mcg Epitalon per eye by parabulbar injection for 10 consecutive days against a conventionally-treated control group, no side effects reported in the treated group — and that summary, not the primary paper's own text, is this page's source for those numbers. This is a short, ocular-route report, not systemic or long-term human data, and no statement of randomization was found in either source. The decades-long Russian gerontology mortality-reduction cohort research (Khavinson and colleagues, St. Petersburg Institute of Bioregulation and Gerontology, PMID 14523363) studied Thymalin and Epithalamin — natural gland-extract preparations that are related but distinct from the synthetic AEDG peptide sold as Epitalon. Epitalon's own other strongest evidence is a rat reproductive-aging model (Arutjunyan et al. 2012, PMID 23237594) and in vitro human-cell telomerase work.

The telomerase activation mechanism is the most scientifically interesting claim. It was originally a single-source finding from the Khavinson lab (2003). A 2025 cell-culture study from an unaffiliated UK group (Al-Dulaimi et al., Biogerontology) tested two breast-cancer cell lines plus normal epithelial cells and fibroblasts, and reported dose-dependent telomere length extension in the normal cells via hTERT upregulation; a published correction (PMID 41240216) replaced three of its figures. Both data sets are cell culture; neither measures the effect in living humans.

Research-grade material is sold by specialty peptide vendors in the US. Quality varies dramatically; verify Certificate of Analysis.

Anti-doping: Epitalon is NOT currently on the WADA prohibited list. The Russian human cohort data is the strongest evidence available for Epitalon's longevity claims; long-term safety appears excellent in this dataset.

Epitalon FAQ

Is Epitalon FDA-approved?

No. Epitalon is not FDA-approved for any indication and has not been through Western clinical trials. The bulk of clinical evidence comes from Russian gerontology research (Khavinson and colleagues, St. Petersburg Institute of Bioregulation and Gerontology). It is sold as a research-grade peptide.

Does Epitalon really lengthen telomeres?

Khavinson's lab reported telomerase activation and telomere lengthening in human somatic cells in culture. In a 2003 mouse study (Anisimov et al., PMID 14501183; 54 mice per group), Epitalon did not change mean lifespan; maximum lifespan was 12.3% longer than in controls. A 2025 cell-culture study from an unaffiliated UK group (Al-Dulaimi et al., Biogerontology) tested two breast-cancer cell lines plus normal epithelial cells and fibroblasts. It reported telomere lengthening via hTERT upregulation in the normal cells and via ALT in the cancer lines; a published correction (PMID 41240216) replaced three of its figures. Both groups' data are cell culture; neither establishes the size of any effect in living organisms.

What's the difference between Epitalon and Epithalamin?

Epithalamin is a natural pineal gland extract studied by Khavinson and colleagues for decades in Soviet-era gerontology research. Epitalon is a synthetic tetrapeptide (AEDG: alanine-glutamate-aspartate-glycine) developed in the 1980s as a short-peptide analog of epithalamin. Epitalon retains the key biological effects of the parent extract in a defined, reproducible synthetic form.

How long until I see results?

Acute effects (sleep quality, circadian rhythm) are measurable in 1–2 weeks of cycling. Telomerase activation effects accumulate over months. Multi-cycle protocols typically run 2–4 cycles over a year. Long-term effects (the framing in Russian cohort research) are measured over years, not weeks.

Can I take Epitalon with NAD+ or other longevity peptides?

Yes — Epitalon + NAD+ is a common longevity stack pairing (cellular metabolism + cellular aging). Compatible with standard longevity protocols including resveratrol, NMN, omega-3, vitamin D. Often combined with GHK-Cu for cellular regeneration + telomere protection. No documented major drug interactions at standard doses.

Is Epitalon safe long-term?

No long-term human safety data exists for synthetic Epitalon itself. The 20+ year Russian cohort safety record often cited for this compound is from Thymalin and Epithalamin (natural gland-extract preparations), not the synthetic AEDG peptide. The one identified short-term human study of synthetic Epitalon — Khavinson et al. 2002 (PMID 12195242), retinitis pigmentosa via parabulbar ocular injection; a 2025 review [3] reports it as 162 patients over 10 consecutive days — reported no side effects, but that is a 10-day ocular-route study, not evidence about long-term or systemic (injected-under-the-skin) use. Beyond that, Epitalon's evidence is a rat model and in vitro human-cell work. Cycling rather than continuous use is the community convention. Telomerase activation is a theoretical concern in cancer contexts; no study of Epitalon in people with cancer was found.

What is the optimal dosing schedule?

There is no trial-derived dosing schedule for subcutaneous, longevity-focused use of Epitalon — the only human dose on record used a different route (parabulbar/ocular injection) for a different indication (Retinitis pigmentosa). The commonly reported community cycle is 5–10 mg total dose per cycle, divided as 0.5–1 mg subcutaneously daily for 10–20 days, repeated 2–4 times per year with 2–6 months between cycles, with bedtime injection preferred to align with natural pineal/melatonin pathway timing — but this schedule is community convention, not derived from any cited trial.

Where can I buy Epitalon?

Epitalon is sold by specialty research peptide vendors in the US. Quality varies dramatically — verify Certificate of Analysis. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. https://pubmed.ncbi.nlm.nih.gov/12937682/
  2. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. Correction published: Biogerontology. 2025;27(1):1, PMID 41240216 (Figs. 1–3 replaced). https://pubmed.ncbi.nlm.nih.gov/40908429/
  3. Araj SK, Brzezik J, et al. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
  4. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-49.
  5. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40.
  6. Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23(Suppl 3):11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/
  7. Wikipedia. Epithalon. https://en.wikipedia.org/wiki/Epithalon
  8. Arutjunyan A, Kozina L, Milyutina Y, Korenevsky A, Stepanov M, Arutyunov V. Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats. Curr Aging Sci. 2012;5(3):178-85. https://pubmed.ncbi.nlm.nih.gov/23237594/
  9. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. https://pubmed.ncbi.nlm.nih.gov/12195242/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Bulletin of Experimental Biology and Medicine / PubMed · 2003Abstract open
Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells →

Khavinson VK, Bondarev IE, Butyugov AA

The foundational study establishing Epitalon’s telomerase-activating properties. Using human fetal lung fibroblast cell cultures and the TRAP (Telomeric Repeat Amplification Protocol) assay, the researchers demonstrated that Epitalon activated expression of the hTERT telomerase catalytic subunit, significantly increased telomerase enzyme activity, and extended the proliferative lifespan of cells beyond the Hayflick limit — from termination at the 34th passage to continued division past the 44th passage, an extension of more than 10 additional cell doublings. This was the first study establishing that a simple tetrapeptide could reactivate telomerase in normal human somatic cells, a finding with profound theoretical implications for aging biology.

Biogerontology / PubMed · 2025Open Access
Epitalon Increases Telomere Length in Human Cell Lines Through Telomerase Upregulation or ALT Activity →

Al-Dulaimi S, Thomas R, Matta S, Roberts T

A 2025 cell-culture study by a UK research group unaffiliated with the Khavinson lab. It treated two breast-cancer cell lines (21NT, BT474) and normal epithelial cells and fibroblasts with Epitalon. The authors report dose-dependent telomere length extension in the normal cells through hTERT and telomerase upregulation, and telomere extension in the cancer lines through ALT (Alternative Lengthening of Telomeres), with only minor ALT activity in normal cells. A published correction (Biogerontology, PMID 41240216) replaced Figures 1–3. It is a second group's cell-culture report, not animal or human evidence.

International Journal of Molecular Sciences / PMC · 2025Open Access
Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties →

Araj SK, Brzezik J, et al.

A comprehensive 2025 review synthesizing the full body of Epitalon research across telomere biology, antioxidant activity, lifespan extension, cancer research, and circadian regulation. Key findings documented: Epitalon increased lifespan of Drosophila by up to 16%; increased antioxidant enzyme activities (SOD, glutathione peroxidase) in aging rats; reduced spontaneous tumor incidence and metastases in mice; increased telomere lengths in blood cells of elderly humans aged 60–65 and 75–80; and restored melatonin secretion in aged monkeys and humans. The review also covers Epitalon’s DNA-binding mechanism — specifically its interaction with ATTTC sequences in the promoter region of the telomerase gene — providing a molecular explanation for its telomerase-activating effect.

LongevityTelomerase ActivatorPineal PeptideResearch-Grade

Related Peptides

NAD+GHK-CuThymosin Alpha-1DSIP

Comparisons

Epitalon vs NAD+

We may earn commissions from peptide vendor affiliate links.

Have a question about Epitalon? Send us an email